Skip Navigation

Heather Jacene, MD


Radiology

Make an Appointment

Physician

  • Clinical Director, Nuclear Medicine/PET-CT
  • Associate Program Director, Brigham and Women's Joint Program in Nuclear Medicine
  • Senior Physician
  • Assistant Professor of Radiology, Harvard Medical School

Centers/Programs

Clinical Interests

  • Imaging
  • Inflammatory breast cancer
  • Lymphoma
  • Nuclear medicine
  • Radiotherapy with unsealed sources

Contact Information

  • Appointments877-332-4294
  • Office Phone Number617-632-3767
  • Fax617-632-3581

Board Certification:

  • Nuclear Medicine, 2004

Fellowship:

  • Johns Hopkins University, Nuclear Medicine/PET-CT

Residency:

  • Johns Hopkins University, Nuclear Medicine

Medical School:

  • University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School

Research

Rosica D, Cheng SC, Hudson M, Sakellis C, Van den Abbeele AD, Kim CK, Jacene HA. Effects of hyperglycemia on fluorine-18-fluorodeoxyglucose biodistribution in a large oncology clinical practice. Nucl Med Commun. 2018 May; 39(5):417-422.
View in: PubMed

Jacene H, Gomella L, Yu EY, Rohren EM. Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations. Clin Genitourin Cancer. 2018 Mar 23.
View in: PubMed

Karls S, Shah H, Jacene H. PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up. Semin Nucl Med. 2018 Jan; 48(1):37-49.
View in: PubMed

Kamran SC, Jacene HA, Chen YH, Mauch PM, Ng AK. Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD?×?two cycles followed by FDG-PET/CT restaging and 20?Gy of involved-site radiotherapy. Leuk Lymphoma. 2017 Sep 22; 1-7.
View in: PubMed

Alabed YZ, Cheng SC, Mudge C, Sakellis C, Van den Abbeele AD, Campos SM, Jacene HA. Surveillance Imaging in Patients With Endometrial Cancer in First Remission. Curr Probl Diagn Radiol. 2017 Aug 24.
View in: PubMed

Jacene H, Crandall J, Kasamon YL, Ambinder RF, Piantadosi S, Serena D, Kasecamp W, Wahl RL. Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma. Mol Imaging Biol. 2017 06; 19(3):429-436.
View in: PubMed

Nakhlis F, Regan MM, Warren LE, Bellon JR, Hirshfield-Bartek J, Duggan MM, Dominici LS, Golshan M, Jacene HA, Yeh ED, Mullaney EE, Overmoyer B. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer. Ann Surg Oncol. 2017 Sep; 24(9):2563-2569.
View in: PubMed

O JH, Jacene H, Luber B, Wang H, Huynh MH, Leal JP, Wahl RL. Quantitation of Cancer Treatment Response by 18F-FDG PET/CT: Multicenter Assessment of Measurement Variability. J Nucl Med. 2017 Sep; 58(9):1429-1434.
View in: PubMed

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 01 12; 376(2):125-135.
View in: PubMed

Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, Hoos A, Barrington SF, Armand P. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016 11 24; 128(21):2489-2496.
View in: PubMed

McKay RR, Jacobus S, Fiorillo M, Ledet EM, Cotogna PM, Steinberger AE, Jacene HA, Sartor O, Taplin ME. Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. Clin Genitourin Cancer. 2017 04; 15(2):e289-e298.
View in: PubMed

Van den Abbeele AD, Krajewski KM, Tirumani SH, Fennessy FM, DiPiro PJ, Nguyen QD, Harris GJ, Jacene HA, Lefever G, Ramaiya NH. Cancer Imaging at the Crossroads of Precision Medicine: Perspective From an Academic Imaging Department in a Comprehensive Cancer Center. J Am Coll Radiol. 2016 Apr; 13(4):365-71.
View in: PubMed

Tirumani SH, Sakellis C, Jacene H, Shinagare AB, Munshi NC, Ramaiya NH, Van den Abbeele AD. Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome. Clin Nucl Med. 2016 Jan; 41(1):e7-13.
View in: PubMed

Mingos M, Howard S, Giacalone N, Kozono D, Jacene H. Systemic Immune Response to Vaccination on FDG-PET/CT. Nucl Med Mol Imaging. 2016 Dec; 50(4):358-361.
View in: PubMed

Mandelker D, Dal Cin P, Jacene HA, Armand P, Stone RM, Lindeman NI. Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing. Exp Hematol Oncol. 2015; 4:30.
View in: PubMed

Warren LE, Guo H, Regan MM, Nakhlis F, Yeh ED, Jacene HA, Hirshfield-Bartek J, Overmoyer BA, Bellon JR. Inflammatory breast cancer and development of brain metastases: risk factors and outcomes. Breast Cancer Res Treat. 2015 May; 151(1):225-32.
View in: PubMed

Warren LE, Guo H, Regan MM, Nakhlis F, Yeh ED, Jacene HA, Hirshfield-Bartek J, Overmoyer BA, Bellon JR. Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management. Ann Surg Oncol. 2015 Aug; 22(8):2483-91.
View in: PubMed

Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics. 2015 Mar-Apr; 35(2):424-37.
View in: PubMed

Tirumani SH, LaCasce AS, Jacene HA. Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma. PET Clin. 2015 Apr; 10(2):207-25.
View in: PubMed

Abi-Ghanem AS, McGrath MA, Jacene HA. Radionuclide therapy for osseous metastases in prostate cancer. Semin Nucl Med. 2015 Jan; 45(1):66-80.
View in: PubMed

Saboo SS, Ramaiya N, Jacene H, Rainville I, Diller L, Hornick JL, George S. Synchronous small bowel and atypical primary leiomyosarcoma of inferior vena cava in a patient with RB1 mutation. Abdom Imaging. 2014 Feb; 39(1):33-9.
View in: PubMed

Grant P, Sakellis C, Jacene HA. Gynecologic oncologic imaging with PET/CT. Semin Nucl Med. 2014; 44(6):461-78.
View in: PubMed

Domachevsky L, Jacene HA, Sakellis CG, Kim CK. Postradiation changes in tissues: evaluation by imaging studies with emphasis on fluorodeoxyglucose-PET/computed tomography and correlation with histopathologic findings. PET Clin. 2014 Apr; 9(2):217-35.
View in: PubMed

Yeh ED, Jacene HA, Bellon JR, Nakhlis F, Birdwell RL, Georgian-Smith D, Giess CS, Hirshfield-Bartek J, Overmoyer B, Van den Abbeele AD. What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach. Radiographics. 2013 Nov-Dec; 33(7):2003-17.
View in: PubMed

Tirumani SH, Jagannathan JP, Krajewski KM, Shinagare AB, Jacene H, Ramaiya NH. Imatinib and beyond in gastrointestinal stromal tumors: A radiologist's perspective. AJR Am J Roentgenol. 2013 Oct; 201(4):801-10.
View in: PubMed

Pyo J, Won Kim K, Jacene HA, Sakellis CG, Brown JR, Van den Abbeele AD. End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis. Clin Cancer Res. 2013 Dec 01; 19(23):6566-77.
View in: PubMed

Hawryluk EB, O'Regan KN, Sheehy N, Guo Y, Dorosario A, Sakellis CG, Jacene HA, Wang LC. Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center. J Am Acad Dermatol. 2013 Apr; 68(4):592-9.
View in: PubMed

Zukotynski K, Lewis A, O'Regan K, Jacene H, Sakellis C, Almodovar S, Israel D. PET/CT and renal pathology: a blind spot for radiologists? Part 2--lymphoma, leukemia, and metastatic disease. AJR Am J Roentgenol. 2012 Aug; 199(2):W168-74.
View in: PubMed

Zukotynski K, Lewis A, O'Regan K, Jacene H, Sakellis C, Krajewski K, Israel D. PET/CT and renal pathology: a blind spot for radiologists? Part 1, primary pathology. AJR Am J Roentgenol. 2012 Aug; 199(2):W163-7.
View in: PubMed

Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):e647-54.
View in: PubMed

Graham MM, Jacene HA. Molecular imaging training for nuclear medicine residents. J Nucl Med. 2012 Apr; 53(4):655-7.
View in: PubMed

Kasamon YL, Jacene HA, Gocke CD, Swinnen LJ, Gladstone DE, Perkins B, Link BK, Popplewell LL, Habermann TM, Herman JM, Matsui WH, Jones RJ, Ambinder RF. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood. 2012 May 03; 119(18):4129-32.
View in: PubMed

Jacene H. Molecular imaging training course debuts. J Nucl Med. 2012 Jan; 53(1):16NA.
View in: PubMed

Jacene HA, Cohade CC, Zhang Z, Wahl RL. The relationship between patients' serum glucose levels and metabolically active brown adipose tissue detected by PET/CT. Mol Imaging Biol. 2011 Dec; 13(6):1278-83.
View in: PubMed

Kasamon YL, Jacene HA, Swinnen LJ, Popplewell L, Link BK, Habermann TM, Herman JM, Jones RJ, Ambinder RF. Multicenter phase II study of rituximab-ABVD in classic Hodgkin lymphoma (cHL). J Clin Oncol. 2011 May 20; 29(15_suppl):8039.
View in: PubMed

Baechler S, Hobbs RF, Jacene HA, Bochud FO, Wahl RL, Sgouros G. Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab. J Nucl Med. 2010 Dec; 51(12):1878-84.
View in: PubMed

Messersmith WA, Jimeno A, Jacene H, Zhao M, Kulesza P, Laheru DA, Kahn Y, Spira A, Dancey J, Iacobuzio-Donahue C, Donehower RC, Carducci M, Rudek MA, Hidalgo M. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer. 2010 Dec; 9(5):297-304.
View in: PubMed

Goudarzi B, Jacene HA, Wahl RL. Measuring the "unmeasurable": assessment of bone marrow response to therapy using FDG-PET in patients with lymphoma. Acad Radiol. 2010 Sep; 17(9):1175-85.
View in: PubMed

Chien D, Jacene H. Imaging of parathyroid glands. Otolaryngol Clin North Am. 2010 Apr; 43(2):399-415, x.
View in: PubMed

Hobbs RF, Baechler S, Wahl RL, He B, Song H, Esaias CE, Frey EC, Jacene H, Sgouros G. Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy. J Nucl Med. 2010 Mar; 51(3):368-75.
View in: PubMed

Baba S, Jacene HA, Engles JM, Honda H, Wahl RL. CT Hounsfield units of brown adipose tissue increase with activation: preclinical and clinical studies. J Nucl Med. 2010 Feb; 51(2):246-50.
View in: PubMed

Jacene HA, Leboulleux S, Baba S, Chatzifotiadis D, Goudarzi B, Teytelbaum O, Horton KM, Kamel I, Macura KJ, Tsai HL, Kowalski J, Wahl RL. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med. 2009 Nov; 50(11):1760-9.
View in: PubMed

Jacene HA, Ginsburg P, Kwon J, Nguyen GC, Montgomery EA, Bayless TM, Wahl RL. Prediction of the need for surgical intervention in obstructive Crohn's disease by 18F-FDG PET/CT. J Nucl Med. 2009 Nov; 50(11):1751-9.
View in: PubMed

Lyford-Pike S, Ha PK, Jacene HA, Saunders JR, Tufano RP. Limitations of PET/CT in determining need for neck dissection after primary chemoradiation for advanced head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 2009; 71(5):251-6.
View in: PubMed

Jacene HA, Wahl RL. The importance of brown adipose tissue. N Engl J Med. 2009 Jul 23; 361(4):417-8; author reply 419-20.
View in: PubMed

He B, Wahl RL, Sgouros G, Du Y, Jacene H, Kasecamp WR, Flinn I, Hammes RJ, Bianco J, Kahl B, Frey EC. Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies. Med Phys. 2009 May; 36(5):1595-601.
View in: PubMed

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009 May; 50 Suppl 1:122S-50S.
View in: PubMed

Ma WW, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, Wahl R, Endres C, Jimeno A, Pomper MG, Hidalgo M. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol. 2009 Jun 01; 27(16):2697-704.
View in: PubMed

He B, Du Y, Segars WP, Wahl RL, Sgouros G, Jacene H, Frey EC. Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake. Med Phys. 2009 Feb; 36(2):612-9.
View in: PubMed

Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab. 2009 Apr; 94(4):1310-6.
View in: PubMed

Jacene HA, Filice R, Kasecamp W, Wahl RL. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med. 2009 Jan; 50(1):8-17.
View in: PubMed

Bonekamp D, Jacene H, Bartelt D, Aygun N. Conversion of FDG PET activity of fibrous dysplasia of the skull late in life mimicking metastatic disease. Clin Nucl Med. 2008 Dec; 33(12):909-11.
View in: PubMed

Brenner ME, Jacene HA. Recurrent or residual hyperparathyroidism and thyroid cancer effectively evaluated with scintigraphy. Otolaryngol Clin North Am. 2008 Dec; 41(6):1117-33, viii-ix.
View in: PubMed

Lodge MA, Jacene HA, Pili R, Wahl RL. Reproducibility of tumor blood flow quantification with 15O-water PET. J Nucl Med. 2008 Oct; 49(10):1620-7.
View in: PubMed

Goudarzi B, Jacene HA, Wahl RL. Diagnosis and differentiation of bronchioloalveolar carcinoma from adenocarcinoma with bronchioloalveolar components with metabolic and anatomic characteristics using PET/CT. J Nucl Med. 2008 Oct; 49(10):1585-92.
View in: PubMed

Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, Khan Y, Zhao M, Jacene H, Messersmith WA, Laheru D, Donehower RC, Garrett-Mayer E, Baker SD, Hidalgo M. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol. 2008 Sep 01; 26(25):4172-9.
View in: PubMed

Swinnen LJ, Flinn IW, Kahl BS, Frey E, Rogers K, Jung M, Jacene H, Wahl RL. Phase I trial of yttrium 90 ibritumomab tiuxetan (90Y-RIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). J Clin Oncol. 2008 May 20; 26(15_suppl):8565.
View in: PubMed

He B, Wahl RL, Du Y, Sgouros G, Jacene H, Flinn I, Frey EC. Comparison of residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--Monte Carlo simulation studies. IEEE Trans Med Imaging. 2008 Apr; 27(4):521-30.
View in: PubMed

Mosley C, Jacene HA, Holz A, Grand DJ, Wahl RL. Extramedullary hematopoiesis on F-18 FDG PET/CT in a patient with metastatic colon carcinoma. Clin Nucl Med. 2007 Nov; 32(11):878-80.
View in: PubMed

Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007 Nov; 48(11):1767-76.
View in: PubMed

Jacene HA, Goudarzi B, Wahl RL. Scalene muscle uptake: a potential pitfall in head and neck PET/CT. Eur J Nucl Med Mol Imaging. 2008 Jan; 35(1):89-94.
View in: PubMed

Melton GB, Lavely WC, Jacene HA, Schulick RD, Choti MA, Wahl RL, Gearhart SL. Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy. J Gastrointest Surg. 2007 Aug; 11(8):961-9; discussion 969.
View in: PubMed

Lucas RG, Jacene H, Harolds J, Barnes L, Maurer A. Nuclear medicine training for radiology residents: needs assessment survey. Acad Radiol. 2007 Mar; 14(3):301-5.
View in: PubMed

Jacene HA, Stearns V, Wahl RL. Lymphadenopathy resulting from acute hepatitis C infection mimicking metastatic breast carcinoma on FDG PET/CT. Clin Nucl Med. 2006 Jul; 31(7):379-81.
View in: PubMed

Jacene HA, Ishimori T, Engles JM, Leboulleux S, Stearns V, Wahl RL. Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. J Nucl Med. 2006 Jun; 47(6):950-6.
View in: PubMed

Ha PK, Hdeib A, Goldenberg D, Jacene H, Patel P, Koch W, Califano J, Cummings CW, Flint PW, Wahl R, Tufano RP. The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2006 Jan; 132(1):12-6.
View in: PubMed

Díaz-Montes TP, Jacene HA, Wahl RL, Bristow RE. Combined FDG-positron emission tomography and computed tomography for the detection of ovarian cancer recurrence in an inguinal hernia sac. Gynecol Oncol. 2005 Sep; 98(3):510-2.
View in: PubMed

Subhas N, Patel PV, Pannu HK, Jacene HA, Fishman EK, Wahl RL. Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics. 2005 Jul-Aug; 25(4):1031-43.
View in: PubMed

Jacene HA, Cohade C, Wahl RL. F-18 FDG PET/CT in acute respiratory distress syndrome: a case report. Clin Nucl Med. 2004 Dec; 29(12):786-8.
View in: PubMed

Jacene HA, Patel PP, Chin BB. 2-Deoxy-2-[18F] fluoro-D-glucose uptake in intercostal respiratory muscles on positron emission tomography/computed tomography: smokers versus nonsmokers. Mol Imaging Biol. 2004 Nov-Dec; 6(6):405-10.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston MA, 02215
Get Directions

Top